Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
NCT00583622
Terminated
The goal of this clinical research study is to learn if bevacizumab, when given in combination with gemcitabine, docetaxel, melphalan and carboplatin, or with topotecan, cyclophosphamide and melphalan (if you are older than 60 or have an allergy to carboplatin), can help to control ovarian cancer during a stem cell transplant. The safety of this drug combination will also be studied.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
04/10/2013
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer
Register for Updates
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
NCT00756847
Completed
The purpose of this study is to evaluate the safety and tolerability of XL147 in combination with paclitaxel and carboplatin in adults with solid tumors. XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells. In clinical practice, the combination of paclitaxel and carboplatin is an accepted treatment regimen for various solid tumors, including ovarian cancer, endometrial cancer an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2013
Locations: Investigational Site Number, St. Louis, Missouri +3 locations
Conditions: Cancer, Non-Small Cell Lung Cancer, Endometrial Carcinoma, Ovarian Carcinoma
Register for Updates
S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00006708
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without rituximab for non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2013
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +84 locations
Conditions: Lymphoma
Register for Updates
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
NCT00024284
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining carboplatin and irinotecan in treating children who have refractory solid tumors.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/03/2013
Locations: Arizona Cancer Center, Tucson, Arizona +6 locations
Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Register for Updates
Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
NCT00148668
Completed
The purpose of this study is to find out what effects the preoperative combination therapies of herceptin/navelbine or herceptin/taxotere/carboplatin will have on patients with early stage HER-2 positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2013
Locations: Yale Cancer Center, New Haven, Connecticut +3 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
NCT00003406
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel, ifosfamide, and carboplatin followed by peripheral stem cell transplantation in treating patients with refractory cancer.
Gender:
ALL
Ages:
65 years and below
Trial Updated:
03/25/2013
Locations: Midwestern Regional Medical Center, Zion, Illinois
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
NCT00193596
Completed
In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with carcinoma of unknown primary site.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2013
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +30 locations
Conditions: Neoplasms, Unknown Primary
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
NCT00281788
Completed
RATIONALE: Drugs used in chemotherapy, such as capecitabine, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with carboplatin, paclitaxel, and radia... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2013
Locations: Duke Comprehensive Cancer Center, Durham, North Carolina
Conditions: Esophageal Cancer
Register for Updates
Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer
NCT00581971
Completed
This is a single-institution, open-label, non-randomized phase IB/II trial of celecoxib administered concurrently with carboplatin, paclitaxel, and radiation therapy in patients with locally advanced or recurrent squamous cell carcinoma of the head and neck.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
03/13/2013
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cancer
Register for Updates
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
NCT00040872
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapie... Read More
Gender:
ALL
Ages:
50 years and below
Trial Updated:
03/06/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma
Register for Updates
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
NCT00288041
Completed
This phase II trial is studying how well giving bortezomib together with paclitaxel and carboplatin works in treating patients with metastatic melanoma. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may help paclitaxel and carboplatin kill more tum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2013
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma
Register for Updates
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
NCT00429182
Completed
The goal of this clinical research study is to learn the relationship of high-dose chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast cancer. The study also will investigate the role of CTCs in breast cancer.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/28/2013
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
Register for Updates